Myostatin inhibition ranks among the most active areas in muscle research. Block myostatin, and you release a brake on skeletal muscle growth. Two research compounds chase that goal, yet they could hardly differ more in design. MID-35 is a tiny synthetic peptide. By contrast, FLGR242 is a large engineered protein. Furthermore, one comes from academia with peer-reviewed data, while the other arrived recently from a commercial developer. This article compares them as research compounds. Below, we cover what each molecule is, how each works, and where the two diverge.
The Shared Target: Myostatin
Both compounds aim at the same protein. Myostatin, also called growth differentiation factor 8 (GDF-8), belongs to the TGF-β superfamily. Its job is simple: limit muscle size. Because myostatin acts as a negative regulator, it holds skeletal muscle growth in check. The protein signals by binding the activin receptor type IIB (ActRIIB) on muscle cells. Consequently, a Smad2/3 cascade fires. That cascade suppresses muscle protein synthesis and switches on atrophy genes. Animals carrying natural myostatin mutations therefore show dramatic overgrowth — the “double-muscling” phenotype. For this reason, researchers study myostatin blockade against wasting conditions such as sarcopenia and cachexia. Although MID-35 and FLGR242 both interrupt this pathway, they take very different routes.
MID-35: A Minimal Synthetic Peptide
MID-35 stands for Myostatin Inhibitory D-peptide-35. Chemists build it as a 16-residue peptide of roughly 2.4 kDa. Its sequence reads lrxkrwirxkiwriyw-amide, where lowercase letters mark D-amino acids and “x” marks D-cyclohexylglycine. That design serves a clear purpose. Specifically, MID-35 is a retro-inverso peptide. The sequence runs in reverse, and every residue takes the D-form. Since natural enzymes struggle to cut D-peptides, the molecule shrugs off enzymatic breakdown.
The compound descends from an earlier inhibitor, MIPE-1686. Researchers wanted a sturdier version, because MIPE-1686 broke down too quickly. Therefore, they synthesized a panel of retro-inverso D-forms and screened them (Takayama et al., 2022). Among those candidates, MID-35 emerged as the potent, stable winner.
Mechanistically, MID-35 binds myostatin directly. It docks at the very site myostatin uses to engage its type I receptor. By occupying that surface, the peptide blocks the signal before it starts. In cultured C2C12 muscle cells, MID-35 opposed myostatin and promoted myoblast differentiation. Meanwhile, mouse studies delivered the headline result. A single injection into the tibialis anterior raised muscle weight 1.25 to 1.3-fold over 28 days. Follow-up work then traced the timeline. Differentiation markers such as Pax7, MyoD, and myogenin climbed within days. Simultaneously, atrophy genes including Trim63 (MuRF1) and Fbxo32 (Atrogin-1) dropped. Measurable weight gain, however, appeared only around two weeks.
Later studies dug into how that muscle grew. Pax7-positive satellite cells increased, and centralized nuclei appeared in treated fibers. Both signs point toward genuine muscle regeneration. Additionally, the same work tracked sphingosine 1-phosphate, a bioactive sphingolipid tied to muscle mass (ACS Pharmacol Transl Sci, 2026). Levels rose on day 3 in young and adult mice, though aged mice showed no such increase. Separately, researchers paired MID-35 with anamorelin in cancer-cachexia models. That combination improved food intake, grip strength, and survival. Delivery has drawn attention too. One group used iontophoresis, a weak electrical current, to drive MID-35 through skin into muscle (Pharmaceutics, 2023). Kentaro Takayama’s group at Kyoto Pharmaceutical University developed the compound. Kimera supplies MID-35 for laboratory research.
FLGR242: An Engineered Follistatin Protein
FLGR242 flips the approach. Instead of a small designed peptide, it starts from follistatin, a natural secreted glycoprotein. In the body, follistatin binds and neutralizes several TGF-β superfamily members, myostatin among them. Put simply, follistatin acts as one of the body’s own myostatin antagonists. It sequesters the growth factor, so myostatin never reaches its receptor.
According to its developer, FLGR242 is a fragmented, modified version of Follistatin-344 (FST-344). The construct adds two engineered features. First, the developer altered it so that it no longer binds activin. Natural follistatin grabs activin as well as myostatin, and activin binding brings broader, less selective effects. Removing that interaction therefore sharpens the focus on myostatin alone. Second, the protein carries an albumin-binding element. A hydrophilic glycine-serine linker grips serum albumin tightly, at a reported sub-20 nM affinity. Because albumin binding slows clearance, it stretches a protein’s half-life. The developer claims a resulting half-life of up to roughly 19 days.
Interest in FLGR242 has grown alongside GLP-1 research. Since rapid weight loss can strip muscle as well as fat, some researchers look to myostatin blockade for muscle preservation. Its developer positions the compound squarely in that conversation.
Two points about the evidence deserve emphasis. Follistatin’s general biology as a myostatin antagonist rests on solid ground. However, FLGR242’s specific engineering claims — meaning the activin-sparing selectivity and the long half-life — come largely from its manufacturer. Independent peer-reviewed work has not yet confirmed them, unlike MID-35’s core dataset. Notably, FLGR242 reached the market only in late 2025.
Mechanism: Cap the Ligand or Mop It Up
Both compounds stop myostatin from signaling, but their routes diverge. MID-35 caps myostatin at its receptor-binding surface, which delivers a direct competitive block. FLGR242, in contrast, behaves like follistatin. It wraps and neutralizes the ligand, keeping myostatin away from ActRIIB. In short, one compound plugs the ligand’s business end, whereas the other mops the ligand up.
Size and Production: Synthesis versus Bioreactor
The scale gap is enormous. MID-35 is a 16-mer peptide, and chemists make it by solid-phase peptide synthesis. Its structure therefore specifies every D-amino acid exactly. FLGR242, meanwhile, is a follistatin-based protein — far larger and more complex. Manufacturers grow it through recombinant expression, then attach engineered fusion elements. That difference consequently shapes everything downstream, from production to analytical characterization.
Stability: Two Different Tricks
Both molecules endure, though each uses a different trick. MID-35 resists degradation through chemistry. Its D-amino acids and reversed backbone make a poor substrate for proteases. FLGR242 instead endures through pharmacokinetics. Albumin binding keeps the protein circulating far longer than a plain protein would. So one compound dodges the enzymes, while the other simply refuses to leave the bloodstream.
Evidence: Peer Review versus Manufacturer Data
MID-35 stands on a peer-reviewed foundation. Independent academic groups have published its synthesis, its mechanism, and its effects in cells and mice. Although FLGR242 builds on well-studied follistatin biology, its own dataset remains thin. The compound rests largely on manufacturer characterization. For any researcher weighing the two, that gap in evidence quality matters.
Comparison at a Glance
- Modality: MID-35 is a synthetic 16-mer D-peptide, whereas FLGR242 is a recombinant follistatin protein.
- Parent molecule: FLGR242 derives from Follistatin-344, while MID-35 descends from the earlier inhibitor MIPE-1686.
- Mechanism: Both block myostatin, but MID-35 caps its receptor site, whereas FLGR242 sequesters the ligand.
- Selectivity: Its developer altered FLGR242 to spare activin, while MID-35 simply targets myostatin.
- Longevity: D-amino acids protect MID-35 from proteases, whereas an albumin binder keeps FLGR242 circulating.
- Evidence: Peer-reviewed cell and mouse studies back MID-35, but FLGR242 rests on manufacturer data.
- Developer: Kyoto Pharmaceutical University produced MID-35, while a commercial lab produced FLGR242.
Research Status and Sourcing
Both compounds remain research chemicals. Neither has drug approval, and neither has established human safety or efficacy. Instead, their data live in cell cultures, animal models, and manufacturer documentation. Kimera stocks MID-35 and lists it in the peptides catalog. For any peptide, identity and purity confirmation drives reproducible results. Therefore, every Kimera lot ships with third-party COA verification, and we publish each result openly in our public COA archive.
Frequently Asked Questions
What is the main difference between MID-35 and FLGR242?
MID-35 is a small synthetic D-peptide that binds myostatin directly. FLGR242, by contrast, is a large recombinant follistatin protein that sequesters myostatin. Although both hit the same pathway, they use very different molecules.
Do MID-35 and FLGR242 work the same way?
Both prevent myostatin from signaling through ActRIIB. However, MID-35 blocks myostatin’s receptor-binding surface, while FLGR242 neutralizes myostatin the way natural follistatin does.
Why does MID-35 use D-amino acids?
D-amino acids resist enzymatic degradation. Consequently, the retro-inverso design gives MID-35 far greater stability than an ordinary L-peptide.
Has anyone independently confirmed FLGR242’s 19-day half-life?
Not yet. That figure comes from the compound’s developer and reflects its albumin-binding design, rather than an independent peer-reviewed result.
Kimera sells MID-35 for laboratory and research use only. Not for human consumption, nor for medical, veterinary, or household use. FLGR242 is discussed here for comparison and is not sold by Kimera.
References
- Takayama K, et al. Development of myostatin inhibitory D-peptides to enhance the potency, increasing skeletal muscle mass in mice. ACS Med Chem Lett. 2022;13(3):492–498. https://pubs.acs.org/doi/abs/10.1021/acsmedchemlett.1c00705
- Myostatin inhibitory D-peptides induce skeletal muscle hypertrophy along with alteration of bioactive sphingolipid metabolism. ACS Pharmacol Transl Sci. 2026;9(6):1544–1553. https://pubs.acs.org/doi/10.1021/acsptsci.6c00124
- Increasing skeletal muscle mass in mice by non-invasive intramuscular delivery of myostatin inhibitory peptide by iontophoresis. Pharmaceutics. 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058260/
